— Know what they know.
Not Investment Advice

ISPC NASDAQ

iSpecimen Inc.
1W: -17.5% 1M: -30.2% 3M: -59.5% YTD: -90.9% 1Y: -97.9% 3Y: -99.8% 5Y: -100.0%
$1.08
-0.06 (-5.26%)
 
Weekly Expected Move ±7.9%
$1 $1 $1 $1 $1
NASDAQ · Healthcare · Medical - Diagnostics & Research · Tech Score Sell · Power 30 · $2.7M mcap · 3M float · 21.01% daily turnover · Short 26% of daily vol
Smart Money Score
Moderate 50
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$2.7M
52W Range1.0414-50
Volume138,994
Avg Volume529,094
Beta1.62
Dividend—
Analyst Ratings
2 Buy 0 Hold 0 Sell
Consensus Buy
Company Info
CEOShahin Behroyan
Employees7
SectorHealthcare
IndustryMedical - Diagnostics & Research
IPO Date2021-06-17
8 Cabot Road
Woburn, MA 01801
US
781 301 6700
About iSpecimen Inc.

iSpecimen Inc. operates a sophisticated technological platform that effectively bridges the gap between life science researchers and crucial human biological materials. Its proprietary cloud-based system empowers scientists to efficiently locate and access a vast array of biospecimens—such as biofluids, tissues, and living cells—as well as connect with potential study subjects, all sourced from a global network of healthcare providers, including hospitals, laboratories, biobanks, and blood centers. The company develops and manages iSpecimen Marketplace, an innovative online hub that strategically links medical researchers requiring access to subjects, samples, and pertinent data with organizations that hold these invaluable resources. iSpecimen's clientele primarily includes biopharmaceutical firms, in vitro diagnostics companies, and governmental and academic research institutions. The company, established in 2009, is headquartered in Lexington, Massachusetts.

Recent Insider Trades

NameTypeSharesPriceDate
Lee Arphing 0 — 2025-11-07
Liang Yuying 0 — 2024-12-13
LIM ROBERT BRADLEY 0 — 2024-12-09
Dhaliwal Avtar A-Award 168 $5.12 2024-09-25
Dhaliwal Avtar 0 — 2024-09-25

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms